Dan Brennan
Stock Analyst at TD Cowen
(3.92)
# 601
Out of 4,935 analysts
109
Total ratings
48.84%
Success rate
11.06%
Average return
Main Sectors:
Stocks Rated by Dan Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Buy | $13 → $15 | $12.20 | +22.95% | 1 | Aug 6, 2025 | |
| CAI Caris Life Sciences | Initiates: Buy | $32 | $29.75 | +7.56% | 1 | Jul 14, 2025 | |
| GH Guardant Health | Maintains: Buy | $56 → $60 | $54.23 | +10.64% | 2 | May 1, 2025 | |
| WGS GeneDx Holdings | Maintains: Buy | $135 → $110 | $105.13 | +4.63% | 4 | May 1, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $8 → $2.5 | $2.20 | +13.64% | 4 | Mar 21, 2025 | |
| TEM Tempus AI | Reinstates: Buy | $74 | $60.87 | +21.57% | 2 | Feb 5, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $82 → $86 | $40.99 | +109.81% | 6 | Nov 26, 2024 | |
| NTRA Natera | Maintains: Buy | $155 → $175 | $151.95 | +15.17% | 4 | Nov 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Buy | $240 → $250 | $148.74 | +68.08% | 5 | Nov 7, 2024 | |
| BRKR Bruker | Maintains: Hold | $72 → $70 | $30.43 | +130.04% | 1 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $177 | $94.56 | +87.18% | 12 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $86.84 | +65.82% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $363 → $410 | $281.20 | +45.80% | 3 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $315 | $200.56 | +57.06% | 5 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $153 → $160 | $114.62 | +39.59% | 12 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $28 → $30 | $6.32 | +374.68% | 1 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $11.50 | +169.57% | 3 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $648 → $658 | $460.72 | +42.82% | 12 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $51 | $43.15 | +18.19% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2.8 | $0.40 | +599.13% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $5.80 | +244.83% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $57 → $32 | $12.29 | +160.37% | 4 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $545 → $546 | $189.43 | +188.23% | 4 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.66 | +163.16% | 1 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 → $15 | $1.35 | +1,011.11% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $207 → $232 | $158.44 | +46.43% | 6 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $770 → $880 | $1,255.97 | -29.93% | 3 | Oct 7, 2020 |
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $12.20
Upside: +22.95%
Caris Life Sciences
Jul 14, 2025
Initiates: Buy
Price Target: $32
Current: $29.75
Upside: +7.56%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $56 → $60
Current: $54.23
Upside: +10.64%
GeneDx Holdings
May 1, 2025
Maintains: Buy
Price Target: $135 → $110
Current: $105.13
Upside: +4.63%
Maravai LifeSciences Holdings
Mar 21, 2025
Maintains: Neutral
Price Target: $8 → $2.5
Current: $2.20
Upside: +13.64%
Tempus AI
Feb 5, 2025
Reinstates: Buy
Price Target: $74
Current: $60.87
Upside: +21.57%
Exact Sciences
Nov 26, 2024
Maintains: Buy
Price Target: $82 → $86
Current: $40.99
Upside: +109.81%
Natera
Nov 13, 2024
Maintains: Buy
Price Target: $155 → $175
Current: $151.95
Upside: +15.17%
Charles River Laboratories International
Nov 7, 2024
Maintains: Buy
Price Target: $240 → $250
Current: $148.74
Upside: +68.08%
Bruker
Nov 6, 2024
Maintains: Hold
Price Target: $72 → $70
Current: $30.43
Upside: +130.04%
Nov 5, 2024
Maintains: Buy
Price Target: $166 → $177
Current: $94.56
Upside: +87.18%
Nov 5, 2024
Maintains: Buy
Price Target: $141 → $144
Current: $86.84
Upside: +65.82%
Nov 4, 2024
Maintains: Hold
Price Target: $363 → $410
Current: $281.20
Upside: +45.80%
Oct 23, 2024
Maintains: Buy
Price Target: $310 → $315
Current: $200.56
Upside: +57.06%
Aug 22, 2024
Maintains: Buy
Price Target: $153 → $160
Current: $114.62
Upside: +39.59%
Aug 7, 2024
Maintains: Hold
Price Target: $28 → $30
Current: $6.32
Upside: +374.68%
Jul 29, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $11.50
Upside: +169.57%
Jul 25, 2024
Maintains: Buy
Price Target: $648 → $658
Current: $460.72
Upside: +42.82%
Jul 23, 2024
Maintains: Buy
Price Target: $48 → $51
Current: $43.15
Upside: +18.19%
May 13, 2024
Initiates: Buy
Price Target: $2.8
Current: $0.40
Upside: +599.13%
May 1, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $5.80
Upside: +244.83%
May 1, 2024
Downgrades: Hold
Price Target: $57 → $32
Current: $12.29
Upside: +160.37%
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $189.43
Upside: +188.23%
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $2.66
Upside: +163.16%
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.35
Upside: +1,011.11%
Mar 1, 2021
Upgrades: Buy
Price Target: $207 → $232
Current: $158.44
Upside: +46.43%
Oct 7, 2020
Downgrades: Sell
Price Target: $770 → $880
Current: $1,255.97
Upside: -29.93%